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Abstract
Objective: To evaluate the role of oral fenofibrate for lowering neonatal hyperbilirubinemia as compared to placebo. Design: Double-
blind, randomized, placebo-controlled trial. Setting: NICU of tertiary care hospital of North India. Subjects: 50 neonates with neonatal 
hyperbilirubinemia. Neonates (≥35 weeks of gestation), birth weight (1.5-3.5 kg), jaundice beginning at day 3-11 after birth, total 
bilirubin level between 15 and 21 mg/dl, and clinically stable vital signs. Intervention: Neonates were assigned randomly to receive 
either single dose of oral fenofibrate at 10 mg/kg/dose on day 1 of admission and distilled water on the following next day or a single 
dose of oral glucose solution on day 1 and distilled water on the following next day. Malloy-Evelyn method was used to estimate 
the serum total bilirubin levels. All newborns enrolled in this study, received phototherapy. The cases were divided into two groups, 
i.e. study (fenofibrate) group and control group. Measurement of Primary Outcome: Duration of phototherapy. Results: Mean values 
for total serum bilirubin in fenofibrate group at 36 and 48 h after starting of phototherapy were significantly lower in the study group 
than those in the control group (p<0.00001). The mean time needed for phototherapy was also shorter in the study group than control 
group (p<0.0002). No side effects of fenofibrate were observed after a single dose administration. Conclusion: Fenofibrate appears to 
be an effective and safe drug for the treatment of neonatal hyperbilirubinemia. This decreases the duration of phototherapy and thus 
shortens the length of hospital stay.
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Neonatal hyperbilirubinemia is a common problem in the neonatal period occurring in nearly 5-25% neonates [1]. There are several non-pharmacological 
and pharmacological modalities for treating hyperbilirubinemia. 
Nowadays, phototherapy and exchange transfusion are the 
standard therapies for unconjugated hyperbilirubinemia 
in neonates. However, both have their side effects and 
drawbacks [2,3]. Among all the modalities of treatment, 
phototherapy has emerged as the most widely used therapy 
for the treatment and prophylaxis of neonatal unconjugated 
hyperbilirubinemia, but it has several untoward complications 
such as deleterious effect to eyes, high temperature, loose 
stool, and bronze baby syndrome [4]. Pharmacological 
agents introduced for treatment of unconjugated neonatal 
jaundice include phenobarbitone, metalloporphyrins, and 
D-penicillamine [5]. Metalloporphyrins and D-penicillamine 
have not been proved very effective and safe in clinical use [5].
Fibrates have been used for several years as a hypolipidemic 
drug [6]. Fibrates also increase bilirubin conjugation and 
excretion via induction of glucuronyl transferase activity [7]. 
Its potency to induce bilirubin conjugation is many times 
more than phenobarbitone [8]. The effect of clofibrate on 
uncomplicated hyperbilirubinemia was proposed in some 
studies [9,10]. Mohammadzadeh et al. studied the effect of 
clofibrate on reducing serum bilirubin level of neonates beyond 
the first week of life [10]. Clofibrate, however, is no longer 
routinely used for hyperlipidemia in adults due to its adverse 
effect profile. Fenofibrate is now the most widely used fibrate 
in treating hyperlipidemia and has better safety profile than 
clofibrate [11]. The present study was designed to assess the 
effect of fenofibrate on neonatal hyperbilirubinemia in term 
and preterm neonates.
METHODS
This was a double-blind, randomized controlled trial conducted 
in the Department of Pediatrics, in active collaboration with the 
Department of Obstetrics and Gynaecology and Department 
of Pathology, of a tertiary care hospital of North India, from 
August 2013 to October 2014. The protocol was cleared by the 
Institutional Ethics Committee and written informed consent 
was taken from one of the parents before inclusion into the 
study.
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Subjects
Neonates ≥35 weeks of gestation, weighing 1.5-3.5 kg, admitted 
to our NICU with stable vital signs and jaundice beginning at 
day 3-11 after birth and total bilirubin level between 15 and 
21 mg/dl, were screened for inclusion in the study (Fig. 1). 
Exclusion criteria were direct hyperbilirubinemia, ABO 
incompatibility, Rh incompatibility, unstable vital signs, 
metabolic abnormalities, congenital defects, congenital 
infections, and physical abnormalities.
All potentially eligible neonates, not meeting the exclusion 
criteria, were screened for birth weight (1.5-3.5 kg) and serum 
bilirubin level at admission. Neonates with total serum bilirubin 
≥15 mg/dl and ≤21 mg/dl were enrolled in the study after taking 
an informed consent from parents after explaining them about 
the study. At any time, parents were free to withdraw from the 
study.
Sample Size
Considering the admission of our NICU in previous years and 
time limit for study, a sample size with the total of 50 neonates 
was planned.
Interventions
The enrolled neonates were randomly assigned with 
computer-generated random number tables via software named 
random allocation software, to receive either oral fenofibrate 
(study group) or glucose solution (placebo group). Infants in 
both the groups were nursed on servo-controlled, open care 
bed, with skin temperature maintained at 36.5°C. Both groups 
received LED phototherapy under standard conditions, adjusted 
to about 30 cm above the neonate. The study group received a 
single dose of oral fenofibrate at 10 mg/kg/dose, whereas the 
control group received oral glucose solution.
Outcome Variables
Total, direct and indirect bilirubins were measured at 
admission, and after 24, 36, and 48 h of admission. Duration of 
phototherapy was also recorded in all cases.
Data Collection and Monitoring
Blood samples were withdrawn immediately after admission and 
before starting any treatment from both the groups for laboratory 
tests such as complete blood count (CBC), total bilirubin (direct 
and indirect), reticulocyte count, and blood group (ABO and 
Rh of neonates and their mothers). Serum bilirubin, total and 
differential, was recorded at the time of admission and after 24, 
36, and 48 h duration of phototherapy in both groups.
Statistical Analysis
All the data were recorded on predesigned and pretested 
proforma and analyzed statistically. Continuous variables were 
Figure 1: Screening for inclusion criteria
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analyzed by Student’s t-test, and categorical variables were 
analyzed by Chi-square test with Yates correction. Findings 
associated with a p<0.05 were considered significant.
Side Effects
There are some rare side effects reported in adults include 
nausea, vomiting, constipation, diarrhea, heartburn, stomach 
pain, pain in the back, arm, or legs, headache, weakness, muscle 
pain or tenderness, joint pain, fever, blistering or peeling skin, 
rash, redness, swelling, pain, tenderness, or warmth in one 
leg, shortness of breath, pain when breathing, coughing up 
blood [12], but these effects are difficult to monitor in neonates. 
We monitored side effects such as constipation, diarrhea, fever, 
blistering or peeling skin, rash, vomiting in our neonates.
RESULTS
All 50 neonates (25 each in fenofibrate and control group) 
received phototherapy. The fenofibrate (A) group included 
16 males (64%) and 9 females (36%) while control (B) group 
comprised 15 males (60%) and 10 females (40%). There 
were no statistical overt differences between the two groups 
regarding age, sex, weight, and gestational age, mode of 
delivery, maternal age, and type of feeding, and other risks 
factors [Table 1].
The difference in mean total serum bilirubin levels in neonates 
between study and control groups at the time of admission was 
statistically non-significant (p=0.3597). However, the study 
group had significantly lower mean total bilirubin values after 
24, 36, and 48 h as compared to placebo group. The mean serum 
bilirubin levels after 24, 36, and 48 h in study group and control 
group are given in Table 2. The difference in serum bilirubin 
levels between both the groups after 24 h was statistically non-
significant (p=0.269); however, it became significant after 36 
and 48 h of phototherapy (p<0.0001).
The mean duration of phototherapy in fenofibrate group 
was 38.40±11.02 h, which was lower than that of the control 
group (46.67±4 h) which was statistically significant (p=0.048). 
During hospitalization, 48 h after treatment and at the time of 
discharge, none of the neonates had any documented adverse 
effect (Fig. 2).
DISCUSSION
Although fibrates are hypolipidemic drug, it also increases 
bilirubin conjugation and excretion via induction of glucuronyl 
transferase activity. Thus, they decrease jaundice in neonates 
by influencing bilirubin metabolism. In the present study, the 
effect of combination therapy of single dose of fenofibrate 
(10 mg/kg) and phototherapy (study group) was compared with 
phototherapy alone (control group). In our study, 50 neonates, 
gestational age ≥35 weeks and birth weight between 1.5 and 
3.5 kg, having total serum bilirubin at admission between 15 
and 21 mg/dl were divided in the study and control group.
We observed that study group had significantly lower mean 
total bilirubin values after 24, 36, and 48 h as compared to control 
group. The mean duration of phototherapy in fenofibrate group 
was also lower than that of the control group. Kumar et al. [13] 
Figure 2: Trial flow of the study
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and Alasy et al. [14] also reported almost similar findings 
from their study. In our study, there is a greater fall in the total 
serum bilirubin in the fenofibrate-treated group in 24, 36, and 
48 h after admission in comparison to the fenofibrate-treated 
group in Alasy et al. 2013 and Kumar et al. in 2010. This may 
be attributed to the fact that we have used LED phototherapy 
in our study in comparison to conventional phototherapy in 
previous studies.
In 2009, Jaikrishan et al. [15] did a study on another 
hypolipidemic drug and gemfibrozil in late preterm and 
term neonates with moderate jaundice and concluded that 
gemfibrozil is effective in reducing the duration of phototherapy 
significantly. Similarly, clofibrate was also used by researchers 
for treatment and prophylaxis of hyperbilirubinemia of infancy 
at a dose of >100 mg/kg [10] but clofibrate has many side 
effects for which it is an obsolete drug nowadays.
Fenofibrate is very similar to clofibrate in its mechanism 
of action. It is easily available and has better safety profile 
and thus much safer to administer in pediatric age group than 
clofibrate. The present study clearly highlights the efficacy 
of oral fenofibrate in decreasing the level of serum bilirubin 
and duration of phototherapy in neonatal hyperbilirubinemia. 
Fenofibrate administration in neonates having 
hyperbilirubinemia can be a useful approach in decreasing 
serum bilirubin level in the present scenario, where the only 
treatment remains phototherapy and exchange transfusion.
The limitations of this study were small sample size, shorter 
duration of study, and difficulty in monitoring all possible side 
effects of fenofibrate in neonates. Although no side effects of 
fenofibrate were observed after a single dose, further studies 
with a more precise and longer follow-up are needed to prove 
its safety. It should not be used in clinical practice until safety 
evaluation is carried out in further large-scale studies.
CONCLUSIONS
The present study highlights the efficacy of oral fenofibrate 
in decreasing the level of serum bilirubin and duration 
of phototherapy in neonatal hyperbilirubinemia. During 
hospitalization, 48 h after treatment and at the time of discharge, 
none of the neonates documented any adverse effect. Thus, 
fenofibrate appears to be effective and probably safe drug for 
neonatal hyperbilirubinemia.
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